{"id":532849,"date":"2021-03-05T13:38:01","date_gmt":"2021-03-05T13:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=532849"},"modified":"2021-03-05T13:38:01","modified_gmt":"2021-03-05T13:38:01","slug":"gastric-cancer-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastric-cancer-pipeline-assessment-key-companies-and-emerging-drugs_532849.html","title":{"rendered":"Gastric Cancer Pipeline Assessment, Key Companies, And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gastric Cancer Pipeline Assessment, Key Companies, And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Gastric Cancer Pipeline Assessment, Key Companies, And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Gastric Cancer Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Gastric Cancer Market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The <strong>Gastric Cancer Pipeline<\/strong><\/span><span data-mce-mark=\"1\"><strong> report<\/strong> embraces in-depth <\/span><span data-mce-mark=\"1\">commercial <\/span><span data-mce-mark=\"1\">and clinical assessment of the <strong>Gastric Cancer pipeline products<\/strong> from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <\/span><span data-mce-mark=\"1\">Gastric Cancer collaborations<\/span><span data-mce-mark=\"1\">, mergers, licensing,&nbsp;acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<p style=\"text-align: justify;\">Get FREE sample copy at:&nbsp;<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/gastric-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Gastric Cancer Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/c0aac6e7f0c3a9f74da0c96f183e74a9.jpg\" alt=\"Gastric Cancer Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The dynamics of the Gastric Cancer (GC) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020&ndash;2030.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Gastric Cancer market include:<\/strong><br \/>RemeGen <br \/>Innovent Biologics<br \/>Bold Therapeutics<br \/>MacroGenics<br \/>Transcenta<br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Gastric Cancer (GC) therapies covered in the report include<\/strong><br \/>RC48<br \/>BOLD-100<br \/>IBI308<br \/>Margetuximab<br \/>TST001<br \/><strong>And many more.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Gastric Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides detailed insights about companies that are developing therapies for the <\/span><strong>treatment of Gastric Cancer <\/strong><span data-mce-mark=\"1\">with aggregate therapies developed by each company for the same.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the <strong>Gastric Cancer treatment<\/strong>.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Gastric Cancer key companies <\/span><span data-mce-mark=\"1\">involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Gastric Cancer Drugs<\/strong><span data-mce-mark=\"1\"> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the <\/span><strong>Gastric Cancer market<\/strong><span data-mce-mark=\"1\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">&nbsp;<\/span>Scope of the report<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The <\/span><strong>Gastric Cancer Pipeline Report<\/strong><span data-mce-mark=\"1\"> provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and<\/span><span data-mce-mark=\"1\"> MOA type for Gastric Cancer <\/span><span data-mce-mark=\"1\">across the complete product development cycle, including all clinical and non-clinical stages.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It comprises detailed profiles of <\/span><strong>Gastric Cancer therapeutic products<\/strong><span data-mce-mark=\"1\"> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed research and development progress and<\/span><strong> clinical trial of Gastric Cancer<\/strong><span data-mce-mark=\"1\">, results wherever available, are also included in the pipeline study.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across Gastric Cancer.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of novel <strong>therapeutics for Gastric Cancer<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">In the coming years, the <strong>Gastric Cancer market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The companies and academics are working to assess challenges and seek opportunities that could influence <\/span><strong>Gastric Cancer Research &amp; Development<\/strong><span data-mce-mark=\"1\">. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">A detailed portfolio of major pharma players who are involved in fueling the <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Gastric Cancer treatment market<\/strong><\/a><span data-mce-mark=\"1\">. Several potential therapies for Gastric Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Gastric Cancer market size in the coming years.&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Our in-depth analysis of the <\/span><strong>Gastric Cancer pipeline<\/strong><span data-mce-mark=\"1\"><strong> assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. Gastric Cancer&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. Gastric Cancer Current Treatment Patterns<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. Gastric Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Therapeutic Assessment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. Gastric Cancer Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. Gastric Cancer Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. Gastric Cancer Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. Gastric Cancer Product Profiles<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. Gastric Cancer Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. Gastric Cancer Key Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Dormant and Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. Gastric Cancer Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. Gastric Cancer Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. Gastric Cancer Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><br \/><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">Gastric Cancer Market Insight<br \/><\/a><\/strong>DelveInsight&#8217; s Gastric Cancer &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology as well as the market trends in the 7MM.<\/p>\n<p><strong>BioPharma Blog &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/hallux-valgus-market-landscape\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Hallux Valgus Therapeutics Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>About DelveInsight<br \/><\/strong><strong>delveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastric-cancer-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastric-cancer-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;Gastric Cancer Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Gastric Cancer Market. The Gastric Cancer Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gastric-cancer-pipeline-assessment-key-companies-and-emerging-drugs_532849.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-532849","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=532849"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532849\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=532849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=532849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=532849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}